Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00454142
Other study ID # NCI-2009-00197
Secondary ID NCI-2009-00197CD
Status Completed
Phase Phase 2
First received March 27, 2007
Last updated November 16, 2015
Start date August 2007
Est. completion date August 2010

Study information

Verified date January 2012
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with stage IV or recurrent nasopharyngeal cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.


Description:

PRIMARY OBJECTIVES:

I. Determine the efficacy of pazopanib hydrochloride in patients with stage IV or recurrent nasopharyngeal carcinoma.

II. Determine the progression-free survival of patients treated with this drug. III. Determine the toxicity of this drug in these patients. IV. Determine the effect of this drug on angiogenesis inhibition using dynamic contrast-enhanced computed tomography (CT) scan.

V. Determine the pharmacokinetic profile of this drug in these patients. VI. Correlate the effect of this drug on angiogenesis inhibition with the clinical benefit rate and pharmacokinetics.

OUTLINE:

Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for up to 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date August 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed nasopharyngeal carcinoma, meeting the following criteria:

- World Health Organization (WHO) type II-III disease

- Stage IV or recurrent disease

- Must have failed at least 1 prior line of chemotherapy for metastatic or recurrent disease

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 or Karnofsky PS 70-100%

- Life expectancy > 3 months

- WBC >= 3,000/mm³

- Absolute neutrophil count >= 1,500/mm³

- Platelet count >= 100,000/mm³

- Bilirubin normal

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)

- Creatinine normal OR creatinine clearance >= 60 mL/min

- Proteinuria =< 1+ on 2 consecutive dipsticks taken >= 1 week apart

- Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.2 times ULN

- Systolic blood pressure (BP) =< 140 mm Hg and diastolic BP =< 90 mm Hg

- Initiation or adjustment of BP medication allowed provided the average of 3 BP readings are < 140/90 mm Hg prior to study entry

- No history of allergic reaction attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or to other study agents

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- No cerebrovascular accident within the past 6 months

- No history of any of the following diseases within the past 12 weeks:

- Myocardial infarction

- Cardiac arrhythmia

- Admission for unstable angina

- Cardiac angioplasty or stenting

- Venous thrombosis

- No New York Heart Association (NYHA) class III-IV heart failure

- Patients with a history of NYHA class II heart failure are eligible provided they are asymptomatic on treatment

- No significant electrocardiogram (ECG) abnormalities, including QTc prolongation (i.e., QTc >= 500 msec)

- No serious or non-healing wound, ulcer, or bone fracture

- No condition that would impair the ability to swallow and retain pazopanib hydrochloride, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No concurrent uncontrolled illness including, but not limited to, the following:

- Coagulopathy

- Ongoing or active infection

- Psychiatric illness or social situation that would preclude study compliance

- No known allergy to CT contrast agents

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered

- More than 4 weeks since prior radiotherapy

- At least 4 weeks since prior surgery

- No prior antiangiogenesis therapy

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- No concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of pazopanib hydrochloride, as determined by the Principal Investigator

- No concurrent medications that have the potential to interact with the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP3A4

- No concurrent therapeutic warfarin

- Low molecular weight heparin or prophylactic low-dose warfarin allowed

- No concurrent antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
pazopanib hydrochloride
Given PO
Other:
pharmacological study
Correlative studies
Procedure:
computed tomography
Correlative studies

Locations

Country Name City State
Singapore Cancer Therapeutics Research Group Singapore
Singapore National Cancer Centre Singapore
Singapore National University Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Benefit Rate Clinical benefit rate (CBR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST ver 1.0) and assessed by CT or MRI. CBR includes 1) Complete response (CR): disappearance of all lesions; 2) partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions and 3) stable disease (SD): non-PR and non progressive disease. 12 weeks of treatment No
Secondary Response Rate (PR) Per response evaluation criteria in solid tumors (RECIST v1.0) and assessed by MRI or CT: Partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions and non-PD (PD: progressive disease) of non-target lesions. 12 weeks of treatment No
Secondary Progression-free Survival Progression will be evaluated in this study using the new international criteria proposed by RECIST Committee. The sample proportion and associated 95% confidence interval will be reported. From the date of enrollment to the date of first documented progression or death, whichever occurs first, or to the date when the patient was last known to be alive, up to 3 years. No
Secondary Overall Survival From date of enrollment to the study to the date of death from any cause or to the date when the patient was last known to be alive, up to 3 years. No
Secondary Toxicity Profile: Percentage of Participants With Significant (Grade 3/4) Related Adverse Event (AE) The frequencies of grade 3/4 related toxicities were recorded among all participants, and the percentage of participants who experienced significant AEs were reported. From the time of first treatment with pazopanib hydrochloride to up to 30days after completion of treatment Yes
Secondary Pharmacodynamic Study: Tumor Blood Flow at Baseline Dynamic-contrast enhanced computed tomography (DCE-CT) was performed at baseline and Day 28, tumor blood flow was measured.19 of 33 patients had evaluable DCE-CT data. Pretreatment No
Secondary Pharmacodynamic Study: Tumor Blood Flow on Day 28 DCE-CT was performed on Day 28 and tumor blood flow was measured. 19 of 33 patients had evaluable DCE-CT data. 28 days post treatment No
Secondary Pharmacokinetic Study: Percentage of Participants With Trough Concentration at Steady State (Day 28) Above 15 µg/mL Pazopanib pharmacokinetic parameters were estimated on Day 1 and Day 28 (steady state). Trough concentration of pazopanib was measured on Day 28 with blood sampling at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after Day 28 dose. Day 28 of treatment No
Secondary Pharmacokinetic Study: AUC0-24h/Dose on Day 1 AUC 0-24h/dose were measured on day 1 for 26 evaluable participants. Blood sampling is done at zero (pre-dose), 0.5 hr, 1, 2, 3, 4, 5, 6 and 8 hrs after the first dose. Day 1 of treatment No
Secondary Pharmacokinetic Study: Area Under Curve (AUC) 0-24h/Dose on Day 28 AUC 0-24h/dose were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose. Day 28 of treatment No
Secondary Pharmacokinetic Study: Volume of Distribution (Vd/F/Dose) on Day 1 Volume of distribution (Vd/F/dose) were measured on day 1 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 hrs after first dose. Day 1 of treatment No
Secondary Pharmacokinetic Study: Volume of Distribution at Steady State (Vss/F/Dose) on Day 28 Volume of distribution at steady state (Vss/F/Dose) were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose. Day 28 of treatment No
See also
  Status Clinical Trial Phase
Completed NCT01469429 - Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Phase 1/Phase 2
Completed NCT01155609 - L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer N/A
Completed NCT00049283 - Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Phase 1
Completed NCT00407810 - Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00098631 - Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Phase 2
Completed NCT00096512 - S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00055770 - Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Phase 1/Phase 2
Terminated NCT01249443 - Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Phase 1
Completed NCT01637194 - Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Phase 1
Completed NCT01816984 - PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT01674374 - Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Phase 2
Terminated NCT01528137 - Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Phase 1
Completed NCT00114283 - Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase 2
Completed NCT00055913 - Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Terminated NCT01682031 - Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy Phase 2
Completed NCT00492089 - Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Phase 2
Completed NCT00410826 - Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer Phase 2
Completed NCT02245100 - Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
Completed NCT00939627 - Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Phase 2
Terminated NCT00906360 - Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1